Maintenance phase efficacy of sertraline for chronic depression: A randomized controlled trial

JAMA

Volumn 280, Issue 19, 1998, Pages 1665-1672

  Keller, Martin B ^a   Kocsis, James H ^b   Thase, Michael E ^c   Gelenberg, Alan J ^d   Rush, A John ^e   Koran, Lorrin ^f   Schatzberg, Alan ^f   Russell, James ^g   Hirschfeld, Robert ^g   Klein, Daniel ^h   McCullough, James P ⁱ   Fawcett, Jan A ^j   Kornstein, Susan ⁱ   LaVange, Lisa ^k   Harrison, Wilma ^l  

^a BROWN UNIVERSITY   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

^c UNIVERSITY OF PITTSBURGH   (United States)

^d UNIVERSITY OF ARIZONA   (United States)

^e UNIVERSITY OF TEXAS AT DALLAS   (United States)

^f STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g UNIVERSITY OF TEXAS MEDICAL BRANCH   (United States)

^h STONY BROOK UNIVERSITY   (United States)

ⁱ VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

^j RUSH UNIVERSITY MEDICAL CENTER   (United States)

^k IQVIA   (United States)

^l Butler Hospital ^*  (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

PLACEBO; SERTRALINE;

ADULT; ARTICLE; CHRONIC DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; FEMALE; HUMAN; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECURRENCE RISK; TREATMENT OUTCOME;

EID: 0032544990     PISSN: 00987484     EISSN: None     Source Type: Journal    
DOI: 10.1001/jama.280.19.1665     Document Type: Article

References (29)

1. Mintz J, Mintz LI, Arruda MJ, Hwang SS. Treatments of depression and the functional capacity to work. Arch Gen Psychiatry. 1992;49:761-768.
2. Klerman GL, Weissman MM. The course, morbidity, and costs of depression. Arch Gen Psychiatry. 1992;49:831-834.
3. Greenberg PE, Stiglin LE, Finkelstein SN, et al. The economic burden of depression in 1990. J Clin Psychiatry. 1993;54:405-418.
4. Wells KB, Stewart A, Hays RD, et al. The functioning and well-being of depressed patients: results from the Medical Outcomes Study. JAMA. 1989;262:914-919.
5. Von Korff M, Ormel J, Katon W, Lin E. Disability and depression among high utilizers of health care: a longitudinal analysis. Arch Gen Psychiatry. 1992; 49:91-100.
6. Murray CJ, Lopez AD. Global mortality, disability, and the contribution of risk factors: Global Burden of Disease Study. Lancet. 1997;349:1436-1442.
7. Robins L, Regier DA, eds. Psychiatric Disorder in America. New York, NY: Free Press; 1991.
8. Kessler RC, McGonagle KA, Zhao S, et al. Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States: results from the National Comorbidity Survey. Arch Gen Psychiatry. 1994;51:8-19.
9. Maj M, Veltro F, Pirozzi R, Lobrace S, Magliano L. Pattern of recurrence of illness after recovery from an episode of major depression: a prospective study. Am J Psychiatry. 1992;149:795-800.
10. Prien RF, Kupfer DJ. Continuation drug therapy for major depressive episodes. Am J Psychiatry. 1986;143:18-23.
11. Montgomery SA, Dufour H, Brion S, et al. The prophylactic efficacy of fluoxetine in unipolar depression. Br J Psychiatry. 1988;153(suppl 3): 69-76.
12. Doogan DP, Caillard V. Sertraline in the prevention of depression. Br J Psychiatry. 1992;160: 217-222.
13. US Department of Health and Human Services. Depression Guideline Panel, Depression in Primary Care, Treatment of Major Depression. Vol 2. Washington, DC: Agency for Health Care Policy and Research; 1993.
14. NIMH/NIH Consensus Development Conference Statement. Mood disorders. Am J Psychiatry. 1985;142:469-476.
15. Coppen A, Mendelwicz J, Kielholz P. Pharmacotherapy of Depressive Disorders: A Consensus Statement. Geneva, Switzerland: World Health Organization; 1986.
16. Prien RF, Kupfer DJ, Mansky PA, et al. Drug therapy in the prevention of recurrences in unipolar and bipolar affective disorders. Arch Gen Psychiatry. 1984;41:1096-1104.
17. Frank E, Kupfer DJ, Perel JM, et al. Three-year outcomes for maintenance therapies in recurrent depression. Arch Gen Psychiatry. 1990;47: 1093-1099.
18. Robinson DS, Lerfald SC, Bennett B, et al. Continuation and maintenance treatment of major depression with the monoamine oxidase inhibitor phenelzine. Psychopharmacol Bull. 1991;27:31-39.
19. Prescription data for 1997, Ambler, Pa: IMS America.
20. Keller MB, Rush AJ, Thase ME, et al. Evaluating optimal treatment strategies in chronic depression. J Clin Psychiatry. 1998;59:560-568.
21. Hamilton MA. A rating scale for depression. J Neurol Neurosurg Psychiatry. 1960;23:56-62.
22. Montgomery SA, Åsberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry. 1979;134:382-389.
23. Mason BJ, Kocsis JH, Leon AC, et al. Assessment of symptoms and change in dysthymic disorder. In: Kocsis JH, Klein DN, eds. Diagnosis and Treatment of Chronic Depression. New York, NY: Guilford Press; 1995:73-88.
24. Guy W. ECDEU Assessment Manual for Psychopharmacology. Washington, DC: National Institute of Mental Health,US Dept of Health, Education, and Welfare; 1976:76-338.
25. Beck AT, Epstein N, Brown G, Steer RA. Psychometric properties of the Beck Depression Inventory: twenty-five years later. Clin Psychol Rev. 1988;8:77-100.
26. Keller MB, Lavori PW, Friedman B, et al. The Longitudinal Interval Follow-up Evaluation: a comprehensive method for assessing outcome in prospective longitudinal studies. Arch Gen Psychiatry. 1987;44:540-548.
27. Kupfer DJ, Frank E, Perel JM, et al. Five-year outcome for maintenance therapies in recurrent depression. Arch Gen Psychiatry. 1992;49:769-773.
28. Dilsaver SC. Withdrawal phenomena associated with antidepressant and antipsychotic agents. Drug Saf. 1994;10:103-114.
29. Littrell J. Relationship between time since reuptake-blocker antidepressant discontinuation and relapse. Exp Clin Psychopharmacol. 1994;2:82-94.